Guardian Bio
YC S22Boston, US · Founded 2022 · 2 employees · 1 known investors
Guardian Bio develops dendritic cell therapy for solid tumors by generating cDC1 cells from patient stem cells to restore immune function in cancer treatment. The company targets late-stage cancer patients who have dysfunctional antigen presentation.
Founders & leadership· Y Combinator alumni (S22)
Ananya ZutshiinFounder
Ricky BarrettinFounder
A
AnanyaCo-Founder
R
RickyCo-Founder
DP
Dr. PaluckaAcademic Co-Founder, Chair, Scientific Advisory Board
Investors · 1
In the news
- Guardian Bio - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2022
- Guardian Bio - 2025 Funding Rounds & List of Investors - Tracxntracxn.com · 2022